ArticleNature communications2024
Response of treatment-naive brain metastases to stereotactic radiosurgery.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapeutic management of metastatic brain disease: a two-decade meta-analysis of tumor control and neurocognitive outcomes with SRS alone versus SRS plus WBRT.Journal of neuro-oncology · 2026Pooled it
- Stereotactic Radiosurgery for Thalamic Brain Metastases: A Retrospective Analysis and Literature Review.Neurosurgery practice · 2026Article
- Clinical, radiographic, and neuropathologic characterization of peripherally hyperenhancing brain metastases: a novel radiographic entity.Journal of neuro-oncology · 2026Article
- Up to Four-Year Outcomes of Single-Fraction Stereotactic Radiosurgery for Small Brain Metastases: A Competing-Risk Analysis.Cancer medicine · 2026Article
- The impact of CHEK2 status on radiosurgical outcomes in breast cancer brain metastases.Neurosurgical review · 2026Article
- Impact of stereotactic radiosurgery dose on local control and radiation necrosis in metastatic brain lesions: a comparative study.Frontiers in oncology · 2026Article
- An updated review on systemic therapy for brain metastases in non-small cell lung cancer.Translational cancer research · 2025Review
- Distinguishing pseudoprogression from true tumor growth after stereotactic surgery in vestibular schwannoma: a volumetric and clinical trajectory analysis.Radiation oncology (London, England) · 2025Article
- Cesium-131 collagen tile brachytherapy for salvage of recurrent intracranial metastases.Journal of neuro-oncology · 2025Article
- Effect of gamma knife dose rate and tumor-specific factors on treatment outcomes in brain metastases: insights from a cohort study.Journal of cancer research and clinical oncology · 2025Article
- Knowledge, attitudes, and practices towards melanoma among patients with melanoma and their family members: a cross-sectional study.Scientific reports · 2025Article
- Enhancing adoptive cell therapy: future strategies for immune cell radioprotection in neuro-oncology.NPJ precision oncology · 2025Review
- Impact of brain metastasis size at the time of radiotherapy on local control and radiation necrosis.Journal of neuro-oncology · 2025Article
- Article
- Understanding the Radiobiology of Central Nervous System Diseases in the Golden Age of Radiosurgery-Does It Matter?Brain sciences · 2025Review
- Diagnostic Confidence of Contrast-Enhanced T1-Weighted MRI for the Detection of Brain Metastases: 3D FSE versus 3D GRE-Based Sequences.AJNR. American journal of neuroradiology · 2025Article
- Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.Nature reviews. Clinical oncology · 2025Review
- Association between tumor location and toxicity outcomes after stereotactic radiosurgery for brain metastases.Journal of neuro-oncology · 2025Article
- Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- Outcomes of patients with melanoma brain metastases treated with ipilimumab and nivolumab with or without upfront comprehensive stereotactic radiosurgery.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With improvements in survival for patients with metastatic cancer, long-term local control of brain metastases has become an increasingly important clinical priority. While consensus guidelines recommend surgery followed by stereotactic radiosurgery (SRS) for lesions >3 cm, smaller lesions (≤3 cm) treated with SRS alone elicit variable responses. To determine factors influencing this variable response to SRS, we analyzed outcomes of brain metastases ≤3 cm diameter in patients with no prior systemic therapy treated with frame-based single-fraction SRS. Following SRS, 259 out of 1733 (15%) treated lesions demonstrated MRI findings concerning for local treatment failure (LTF), of which 202 /1733 (12%) demonstrated LTF and 54/1733 (3%) had an adverse radiation effect. Multivariate analysis demonstrated tumor size (>1.5 cm) and melanoma histology were associated with higher LTF rates. Our results demonstrate that brain metastases ≤3 cm are not uniformly responsive to SRS and suggest that prospective studies to evaluate the effect of SRS alone or in combination with surgery on brain metastases ≤3 cm matched by tumor size and histology are warranted. These studies will help establish multi-disciplinary treatment guidelines that improve local control while minimizing radiation necrosis during treatment of brain metastasis ≤3 cm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.